Table 1.
Description and comparison of clinical and laboratory characteristics of the study subjects.
| Variables | RCC (n = 318) |
Controls (n = 238) |
P value |
|---|---|---|---|
| Age (years) | 56.83 ± 11.68 | 55.10 ± 13.90 | 0.122 |
| Gender (male/female) | 210/108 | 146/92 | 0.284 |
| BMI (n (%)) | 0.370 | ||
| <25 | 152 (47.80) | 124 (52.10) | |
| ≥25 | 166 (52.20) | 114 (47.90) | |
| Hypertension (n (%)) | 120 (37.74) | 86 (36.13) | 0.723 |
| Diabetes mellitus (n (%)) | 46 (14.47) | 23 (9.66) | 0.093 |
| Smoking (n (%)) | 63 (19.81) | 29 (12.18) | 0.021 |
| RDW (%) | 13.27 ± 0.90 | 12.88 ± 0.51 | <0.001 |
| HB (g/L) | 138.83 ± 15.53 | 143.02 ± 13.69 | 0.001 |
| MCV (fL) | 92.05 ± 4.79 | 92.95 ± 3.77 | 0.013 |
| Platelet (109/L) | 214.04 ± 67.83 | 198.26 ± 48.75 | 0.001 |
| WBC (109/L) | 6.51 ± 1.74 | 5.72 ± 1.32 | <0.001 |
| Albumin (g/L) | 43.00 ± 4.28 | 44.37 ± 3.14 | <0.001 |
| ESR (mm/h) | 11.00 (5.00–19.00) | 6.00 (3.00–10.00) | <0.001 |
| Side (n (%)) | |||
| Left-sided | 135 (42.45) | 131 (55.04) | |
| Right-sided | 176 (55.35) | 96 (40.34) | |
| Two-sided | 7 (2.20) | 11 (4.62) | |
| Pathologic type (n (%)) | |||
| Clear cell carcinoma | 282 (88.68) | ||
| Papillary renal cell carcinoma | 15 (4.72) | ||
| Chromophobe renal cell carcinoma | 11 (3. 46) | ||
| Others | 10 (3.14) | ||
| Stage at diagnosis (n (%)) | |||
| T1 | 239 (75.16) | ||
| T2 | 28 (8.81) | ||
| T3 | 45 (14.15) | ||
| T4 | 6 (1.89) | ||
| M1 | 20 (6.29) | ||
| M0 | 298 (93.71) | ||
| Fuhrman grading of clear cell carcinoma (n (%)) | |||
| Grade I | 22 (7.80) | ||
| Grades I-II | 35 (12.41) | ||
| Grade II | 129 (45.74) | ||
| Grades II-III | 41 (14.54) | ||
| Grade III | 47 (16.67) | ||
| Grades III-IV | 7 (2.48) | ||
| Grade IV | 1 (0.35) |
Data are expressed as n (%), median (IQR), or mean ± SD. BMI: body mass index; RDW: red cell distribution width; HB: hemoglobin; MCV: mean cell volume; WBC: white blood cell; ESR: erythrocyte sedimentation rate.